The catch: authorized and regulatory certainty is low. Retatrutide was in no way to the FDA drug lack record (since it was in no way accredited), so compounders presenting it run underneath more tenuous authorized framing than people who taken care of semaglutide or tirzepatide in the course of the 2023–2024 shortages. Pricing may perhaps change